Noradrenergic Dysfunction in Alzheimer's and Parkinson's Diseases—An Overview of Imaging Studies

Noradrenergic dysfunction contributes to cognitive impairment in Alzheimer's Disease (AD) and Parkinson's Disease (PD). Conventional therapeutic strategies seek to enhance cholinergic and dopaminergic neurotransmission in AD and PD, respectively, and few studies have examined noradrenergic...

Descripción completa

Detalles Bibliográficos
Autores principales: Peterson, Andrew C., Li, Chiang-shan R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Neuroscience
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5938376/
https://www.ncbi.nlm.nih.gov/pubmed/29765316
http://dx.doi.org/10.3389/fnagi.2018.00127

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5938376/
https://www.ncbi.nlm.nih.gov/pubmed/29765316
http://dx.doi.org/10.3389/fnagi.2018.00127

Ejemplares similares